Compare BioNTech SE - ADR (BNTX) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Dollar Tree, Inc. — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while Dollar Tree, Inc. trades at $128.67 (market cap $24.61B). The key difference: BioNTech SE - ADR and Dollar Tree, Inc. are close in size by market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | DLTR | |
|---|---|---|
Market Cap | $23.31B | $24.61B |
Sector | Health | Health |
52-Week High | $119.34 | $141.21 |
52-Week Low | $83.89 | $85.04 |
Enterprise Value | $6.60B | $31.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Dollar Tree (DLTR) trades at $128.76, down 0.47% on the day. The stock exhibits a bullish technical trend, trading near its pivot point of $128 with support at $127. Fundamentally, the company reported a net loss of -$3.03B for 2025 despite strong operating cash flow of $2.86B. Recent news highlights a $2.5 billion share repurchase authorization announced on July 2, 2026 (Business Wire).
The outlook is mixed. Analyst consensus is a 'Buy' with a $126.69 price target, but significant risks exist from recent profitability challenges and competitive pressures. The share repurchase program may support EPS, but investors should weigh the negative net income against improving operational cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
